Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Wall Street Zen to Hold

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Saturday.

A number of other research firms have also recently issued reports on ALNY. Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Chardan Capital lifted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research note on Friday, April 11th. Finally, Royal Bank of Canada lifted their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $319.58.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $307.99 on Friday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a market cap of $40.16 billion, a P/E ratio of -141.93 and a beta of 0.22. The firm has a 50 day simple moving average of $270.09 and a 200 day simple moving average of $259.02. Alnylam Pharmaceuticals has a 52 week low of $152.30 and a 52 week high of $310.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) EPS. Research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the business's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the sale, the chief executive officer now owns 48,948 shares in the company, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALNY. Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $243,000. Empowered Funds LLC lifted its position in Alnylam Pharmaceuticals by 8.0% during the 4th quarter. Empowered Funds LLC now owns 7,630 shares of the biopharmaceutical company's stock worth $1,795,000 after buying an additional 566 shares in the last quarter. Van ECK Associates Corp lifted its position in Alnylam Pharmaceuticals by 18.2% during the 4th quarter. Van ECK Associates Corp now owns 67,818 shares of the biopharmaceutical company's stock valued at $15,958,000 after purchasing an additional 10,419 shares during the period. New York State Teachers Retirement System lifted its position in Alnylam Pharmaceuticals by 10.5% during the 4th quarter. New York State Teachers Retirement System now owns 5,836 shares of the biopharmaceutical company's stock valued at $1,373,000 after purchasing an additional 553 shares during the period. Finally, AustralianSuper Pty Ltd lifted its position in Alnylam Pharmaceuticals by 15.7% during the 4th quarter. AustralianSuper Pty Ltd now owns 4,218 shares of the biopharmaceutical company's stock valued at $993,000 after purchasing an additional 573 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.